Armata Pharmaceuticals Inc ARMP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ARMP is a good fit for your portfolio.
News
-
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update
-
Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference
-
Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023
-
Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus
-
Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
Trading Information
- Previous Close Price
- $2.06
- Day Range
- $2.00–2.30
- 52-Week Range
- $0.83–5.26
- Bid/Ask
- $1.91 / $3.39
- Market Cap
- $76.63 Mil
- Volume/Avg
- 17,119 / 21,087
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 75
- Website
- https://www.armatapharma.com
Valuation
|
Metric
|
ARMP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ARMP
Financial Strength
|
Metric
|
ARMP
|
|---|---|
Quick Ratio | 1.48 |
Current Ratio | 1.67 |
Interest Coverage | −49.71 |
Quick Ratio
ARMP
Profitability
|
Metric
|
ARMP
|
|---|---|
Return on Assets (Normalized) | −52.87% |
Return on Equity (Normalized) | −243.94% |
Return on Invested Capital (Normalized) | −57.85% |
Return on Assets
ARMP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xsgwf | $453.9 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mgcdxx | $90.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jtzjjm | $88.1 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Qvphmrg | $40.3 Bil | |
MRNA
| Moderna Inc | Lptt | $30.1 Bil | |
ARGX
| argenx SE ADR | Twrq | $26.1 Bil | |
BNTX
| BioNTech SE ADR | Bvrs | $23.6 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Pppmtt | $20.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jjlxdlw | $16.9 Bil | |
INCY
| Incyte Corp | Wkkbs | $12.0 Bil |